Clinical Trial Detail

NCT ID NCT03136055
Title Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of California, San Francisco
Indications

neuroendocrine carcinoma

Therapies

Irinotecan + Pembrolizumab

Paclitaxel + Pembrolizumab

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.